Cargando…
Induction chemotherapy followed by radiotherapy versus concurrent chemoradiotherapy in the treatment of different risk locoregionally advanced nasopharyngeal carcinoma
BACKGROUND: This study aimed to investigate the efficiency and toxicities of concurrent chemoradiotherapy (CCRT) and induction chemotherapy (IC) followed by radiotherapy (RT) in different risk locoregionally advanced nasopharyngeal carcinoma (NPC). METHODS: A total of 1814 eligible patients with sta...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7268167/ https://www.ncbi.nlm.nih.gov/pubmed/32536983 http://dx.doi.org/10.1177/1758835920928214 |
_version_ | 1783541559129538560 |
---|---|
author | Liu, Li-Ting Liang, Yu-Jing Guo, Shan-Shan Mo, Hao-Yuan Guo, Ling Wen, Yue-Feng Xie, Hao-Jun Tang, Qing-Nan Sun, Xue-Song Liu, Sai-Lan Li, Xiao-Yun Yang, Jin-Hao Yang, Zhen-Chong Tang, Lin-Quan Chen, Qiu-Yan Mai, Hai-Qiang |
author_facet | Liu, Li-Ting Liang, Yu-Jing Guo, Shan-Shan Mo, Hao-Yuan Guo, Ling Wen, Yue-Feng Xie, Hao-Jun Tang, Qing-Nan Sun, Xue-Song Liu, Sai-Lan Li, Xiao-Yun Yang, Jin-Hao Yang, Zhen-Chong Tang, Lin-Quan Chen, Qiu-Yan Mai, Hai-Qiang |
author_sort | Liu, Li-Ting |
collection | PubMed |
description | BACKGROUND: This study aimed to investigate the efficiency and toxicities of concurrent chemoradiotherapy (CCRT) and induction chemotherapy (IC) followed by radiotherapy (RT) in different risk locoregionally advanced nasopharyngeal carcinoma (NPC). METHODS: A total of 1814 eligible patients with stage II–IVB disease treated with CCRT or IC plus RT were included. The overall survival (OS), progression-free survival (PFS) and distant metastasis-free survival (DMFS) were calculated using the Kaplan–Meier method, and the differences were compared using the log-rank test. RESULTS: Nomograms were developed to predict OS, PFS and DMFS (C-index: 0.71, 0.70 and 0.71, respectively). Patients were then divided into three different risk groups based on the scores calculated by the nomogram for OS. In the low and intermediate-risk group, no significant survival differences were observed between patients treated with IC plus RT alone and CCRT (5-year OS, 97.3% versus 95.6%, p = 0.642 and 87.6% versus 89.7%, p = 0.381, respectively; PFS, 95.9% versus 95.6%, p = 0.325 and 87.6% versus 89.0%, p = 0.160, respectively; DMFS, 97.2% versus 94.8%, p = 0.339 and 87.2% versus 89.3%, p = 0.628, respectively). However, in the high-risk group, IC plus RT displayed an unfavorable 5-year OS (71.0% versus 77.2%, p = 0.022) and PFS (69.4.0% versus 75.4%, p = 0.019) compared with CCRT. A significantly higher incidence of grade 3 and 4 adverse events was documented in patients treated with CCRT than in those treated with IC plus RT in all risk groups (p = 0.040). CONCLUSION: IC followed by RT represents an alternative treatment strategy to CCRT for patients with low and intermediate-risk NPC, but it is not recommended for patients with high-risk NPC. |
format | Online Article Text |
id | pubmed-7268167 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-72681672020-06-11 Induction chemotherapy followed by radiotherapy versus concurrent chemoradiotherapy in the treatment of different risk locoregionally advanced nasopharyngeal carcinoma Liu, Li-Ting Liang, Yu-Jing Guo, Shan-Shan Mo, Hao-Yuan Guo, Ling Wen, Yue-Feng Xie, Hao-Jun Tang, Qing-Nan Sun, Xue-Song Liu, Sai-Lan Li, Xiao-Yun Yang, Jin-Hao Yang, Zhen-Chong Tang, Lin-Quan Chen, Qiu-Yan Mai, Hai-Qiang Ther Adv Med Oncol Original Research BACKGROUND: This study aimed to investigate the efficiency and toxicities of concurrent chemoradiotherapy (CCRT) and induction chemotherapy (IC) followed by radiotherapy (RT) in different risk locoregionally advanced nasopharyngeal carcinoma (NPC). METHODS: A total of 1814 eligible patients with stage II–IVB disease treated with CCRT or IC plus RT were included. The overall survival (OS), progression-free survival (PFS) and distant metastasis-free survival (DMFS) were calculated using the Kaplan–Meier method, and the differences were compared using the log-rank test. RESULTS: Nomograms were developed to predict OS, PFS and DMFS (C-index: 0.71, 0.70 and 0.71, respectively). Patients were then divided into three different risk groups based on the scores calculated by the nomogram for OS. In the low and intermediate-risk group, no significant survival differences were observed between patients treated with IC plus RT alone and CCRT (5-year OS, 97.3% versus 95.6%, p = 0.642 and 87.6% versus 89.7%, p = 0.381, respectively; PFS, 95.9% versus 95.6%, p = 0.325 and 87.6% versus 89.0%, p = 0.160, respectively; DMFS, 97.2% versus 94.8%, p = 0.339 and 87.2% versus 89.3%, p = 0.628, respectively). However, in the high-risk group, IC plus RT displayed an unfavorable 5-year OS (71.0% versus 77.2%, p = 0.022) and PFS (69.4.0% versus 75.4%, p = 0.019) compared with CCRT. A significantly higher incidence of grade 3 and 4 adverse events was documented in patients treated with CCRT than in those treated with IC plus RT in all risk groups (p = 0.040). CONCLUSION: IC followed by RT represents an alternative treatment strategy to CCRT for patients with low and intermediate-risk NPC, but it is not recommended for patients with high-risk NPC. SAGE Publications 2020-06-02 /pmc/articles/PMC7268167/ /pubmed/32536983 http://dx.doi.org/10.1177/1758835920928214 Text en © The Author(s), 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Liu, Li-Ting Liang, Yu-Jing Guo, Shan-Shan Mo, Hao-Yuan Guo, Ling Wen, Yue-Feng Xie, Hao-Jun Tang, Qing-Nan Sun, Xue-Song Liu, Sai-Lan Li, Xiao-Yun Yang, Jin-Hao Yang, Zhen-Chong Tang, Lin-Quan Chen, Qiu-Yan Mai, Hai-Qiang Induction chemotherapy followed by radiotherapy versus concurrent chemoradiotherapy in the treatment of different risk locoregionally advanced nasopharyngeal carcinoma |
title | Induction chemotherapy followed by radiotherapy versus concurrent chemoradiotherapy in the treatment of different risk locoregionally advanced nasopharyngeal carcinoma |
title_full | Induction chemotherapy followed by radiotherapy versus concurrent chemoradiotherapy in the treatment of different risk locoregionally advanced nasopharyngeal carcinoma |
title_fullStr | Induction chemotherapy followed by radiotherapy versus concurrent chemoradiotherapy in the treatment of different risk locoregionally advanced nasopharyngeal carcinoma |
title_full_unstemmed | Induction chemotherapy followed by radiotherapy versus concurrent chemoradiotherapy in the treatment of different risk locoregionally advanced nasopharyngeal carcinoma |
title_short | Induction chemotherapy followed by radiotherapy versus concurrent chemoradiotherapy in the treatment of different risk locoregionally advanced nasopharyngeal carcinoma |
title_sort | induction chemotherapy followed by radiotherapy versus concurrent chemoradiotherapy in the treatment of different risk locoregionally advanced nasopharyngeal carcinoma |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7268167/ https://www.ncbi.nlm.nih.gov/pubmed/32536983 http://dx.doi.org/10.1177/1758835920928214 |
work_keys_str_mv | AT liuliting inductionchemotherapyfollowedbyradiotherapyversusconcurrentchemoradiotherapyinthetreatmentofdifferentrisklocoregionallyadvancednasopharyngealcarcinoma AT liangyujing inductionchemotherapyfollowedbyradiotherapyversusconcurrentchemoradiotherapyinthetreatmentofdifferentrisklocoregionallyadvancednasopharyngealcarcinoma AT guoshanshan inductionchemotherapyfollowedbyradiotherapyversusconcurrentchemoradiotherapyinthetreatmentofdifferentrisklocoregionallyadvancednasopharyngealcarcinoma AT mohaoyuan inductionchemotherapyfollowedbyradiotherapyversusconcurrentchemoradiotherapyinthetreatmentofdifferentrisklocoregionallyadvancednasopharyngealcarcinoma AT guoling inductionchemotherapyfollowedbyradiotherapyversusconcurrentchemoradiotherapyinthetreatmentofdifferentrisklocoregionallyadvancednasopharyngealcarcinoma AT wenyuefeng inductionchemotherapyfollowedbyradiotherapyversusconcurrentchemoradiotherapyinthetreatmentofdifferentrisklocoregionallyadvancednasopharyngealcarcinoma AT xiehaojun inductionchemotherapyfollowedbyradiotherapyversusconcurrentchemoradiotherapyinthetreatmentofdifferentrisklocoregionallyadvancednasopharyngealcarcinoma AT tangqingnan inductionchemotherapyfollowedbyradiotherapyversusconcurrentchemoradiotherapyinthetreatmentofdifferentrisklocoregionallyadvancednasopharyngealcarcinoma AT sunxuesong inductionchemotherapyfollowedbyradiotherapyversusconcurrentchemoradiotherapyinthetreatmentofdifferentrisklocoregionallyadvancednasopharyngealcarcinoma AT liusailan inductionchemotherapyfollowedbyradiotherapyversusconcurrentchemoradiotherapyinthetreatmentofdifferentrisklocoregionallyadvancednasopharyngealcarcinoma AT lixiaoyun inductionchemotherapyfollowedbyradiotherapyversusconcurrentchemoradiotherapyinthetreatmentofdifferentrisklocoregionallyadvancednasopharyngealcarcinoma AT yangjinhao inductionchemotherapyfollowedbyradiotherapyversusconcurrentchemoradiotherapyinthetreatmentofdifferentrisklocoregionallyadvancednasopharyngealcarcinoma AT yangzhenchong inductionchemotherapyfollowedbyradiotherapyversusconcurrentchemoradiotherapyinthetreatmentofdifferentrisklocoregionallyadvancednasopharyngealcarcinoma AT tanglinquan inductionchemotherapyfollowedbyradiotherapyversusconcurrentchemoradiotherapyinthetreatmentofdifferentrisklocoregionallyadvancednasopharyngealcarcinoma AT chenqiuyan inductionchemotherapyfollowedbyradiotherapyversusconcurrentchemoradiotherapyinthetreatmentofdifferentrisklocoregionallyadvancednasopharyngealcarcinoma AT maihaiqiang inductionchemotherapyfollowedbyradiotherapyversusconcurrentchemoradiotherapyinthetreatmentofdifferentrisklocoregionallyadvancednasopharyngealcarcinoma |